Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15725733 | 0.86 | MAPK1 (0.44) | MAPK1KDM4ELMNAHRH3KCNH2 | |
| SCHEMBL11290222 | 0.82 | MAPK1 (0.52) | MAPK1KDM4ELMNA | |
| SCHEMBL1934434 | 0.79 | HRH3 (0.33) | HRH3KCNH2MEN1KMT2APOLB | |
| SCHEMBL9813644 | 0.75 | MEN1 (0.36) | MAPK1LMNAGAAMEN1KMT2A | |
| SCHEMBL2117597 | 0.74 | MAPK1 (0.49) | MAPK1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL11331324 | 0.74 | MAPK1 (0.58) | MAPK1KDM4ELMNA | |
| SCHEMBL9813606 | 0.74 | HSD11B1 (0.36) | LMNAGAAMEN1KMT2APOLB | |
| SCHEMBL15244453 | 0.74 | POLB (0.49) | MAPK1KDM4ELMNAPOLBHTT | |
| Methacrylic Acid SCHEMBL28226575 | 0.73 | MAPK1 (0.40) | MAPK1KDM4ELMNAGAAMEN1 | |
| SCHEMBL10813187 | 0.72 | MAPK1 (0.47) | MAPK1KDM4ELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | claimed |
| CN-101365698-A | 2-urea-4-phenylthiazole derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-11 | — | — | CN | claimed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | claimed |
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| CN-101365698-A | 2-urea-4-phenylthiazole derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-11 | — | — | CN | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | MAPK1 3423/4885KDM4E 114/4885LMNA 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.